The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment.
B reast cancer is biologically and molecularly heterogeneous, exhibiting a spectrum of clinical outcomes ranging from very low risk to very high risk for metastatic recurrence. Timing of life-threatening recurrence varies, occurring months to decades after diagnosis and primary therapy. 1 Molecular profiling has spawned the development of signatures that identify tumors associated with early risk for recurrence 2, 3 and patients who benefit from systemic chemotherapy to reduce that metastatic risk. 4, 5 With the introduction of screening, the distribution of the biologic subtypes of breast cancer shifted, and overall incidence increased by 10% to 20%. Decades later, this increased age-adjusted incidence of breast cancer has remained high. 6 The bulk of the increase has been in early-stage tumors (stage 0, 1), suggesting that screening contributes disproportionately to the diagnosis of biologically more indolent forms of breast cancer. 7, 8 While screening is associated with a relative mortality reduction of 20%, 9, 10 it has increased the diagnosis of low-risk lesions and contributes to overtreatment. 6, 7, 11, 12 Scholarly articles reporting the detection of indolent cancers continue to stir controversy. 13 Unfortunately, clinically lowrisk invasive cancers can recur very late, even after 10 or 15 years. Tools with the capacity to identify ultralow-risk tumors at the time of diagnosis could prevent overtreatment. Cancer type, histologic grade, proliferative index, and stage are associated with lower early metastatic disease risk but do not reliably identify those with sufficiently low long-term (20 years) risk of recurrence to avoid or further reduce therapy. The 70-gene MammaPrint assay (US Food and Drug Administration-cleared) was initially developed as a prognostic tool for women with breast cancer who did not receive adjuvant systemic therapy. The low-vs high-risk threshold was initially used to differentiate recurrence at 5 years after diagnosis because this predicts benefit of systemic chemotherapy. In the recently reported 6693-person randomized clinical trial MINDACT, 5 patients with clinically high but molecularly lowrisk disease without chemotherapy were found to have a 94.7% distant metastasis-free survival at 5 years, even with up to 3 positive nodes and tumors up to 5 cm in size. We previously demonstrated that screening has led to an increase in the proportion of 70-gene low-risk tumors relative to the era prior to the advent of screening. We had set an ultralow-risk threshold (where there were no metastatic events at 5 years, in the original 70-gene cohort) and found that ultralow-risk disease increased from 10% in an unscreened population to 30% in a screened population. 14 However, hormone-positive cancers can recur decades after diagnosis, and two-thirds of recurrences are after 5 years. To truly identify cancers with indolent lesions of epithelial origin behavior (extremely low risk for systemic recurrence), we set a threshold where there were no breast cancer deaths for node-negative patients at 15 years, using 25-year follow-up of the NKI295 series, 1, 15 and this was confirmed in the original European validation set for the 70-gene assay 3 (eFigure 1 and eReference in the Supplement). 16 To independently and rigorously validate the new ultralowrisk threshold, we used a unique resource, the Stockholm randomized clinical trial, STO-3, of postmenopausal women with clinically detected node-negative tumors 3 cm or smaller assigned to tamoxifen vs no adjuvant therapy, which had tissue blocks available and meticulous follow-up.
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Methods
Study Population
The STO-3 study group conducted a randomized clinical trial of tamoxifen from 1976 until 1990 in postmenopausal women. 17 The STO-3 low-risk trial included 1780 lymph nodenegative patients with tumors smaller than or equal to 3 cm in diameter, randomized to 2 years of adjuvant tamoxifen (40 mg daily) vs no adjuvant treatment. In 1983, patients who reconsented and were recurrence-free after 2 years of tamoxifen treatment were randomized to 3 additional years of tamoxifen or no further therapy. The STO-3 trial was approved by the ethical committee at Karolinska Institutet, and participants provided oral consent. Ethics approval was also obtained for the secondary analysis presented in this study. . There were 808 patients with formalin-fixed paraffinembedded (FFPE) tissue blocks available for molecular analysis, with 81 patients excluded because of an insufficient amount of invasive tumor tissue. 18 The patient subset with available FFPE material was well balanced relative to the original cohort with regards to tumor characteristics (tumor size, estrogen receptor status and treatment arm assignment). 19 Immunohistochemical analysis (estrogen receptor, progesterone receptor, ERBB2/HER2, and Ki67) was performed on 727 specimens at a single laboratory. RNA was extracted, and 652 patients had 70-gene signature classification passing the quality check ( Figure 1 ): 339 had received tamoxifen, and 313 had not received adjuvant systemic therapy.
Estrogen-Receptor, Progesterone Receptor, ERBB2/HER2, and Ki67 Immunohistochemical Analysis
The FFPE tissue sections were sectioned at 4 μm and mounted on plus-coated glass slides, shipped to University of California, Davis, and immunohistochemically stained in the CLIA laboratory using a DAKO Autostainer Link 48. 
Statistical Analysis
Kaplan-Meier analysis of 20-year breast cancer-specific survival by MammaPrint risk categories (high-vs low-risk) was performed, and significance assessed using the log-rank test. Similarly, Kaplan-Meier analysis of 20-year breast cancerspecific survival according to 70-gene risk categories were conducted for all patients, as well as within each STO-3 trial treatment arm (tamoxifen or untreated) separately. In addition, analyses of 20-year breast cancer-specific survival by the ultralow-risk threshold, used as the reference category, were performed by multivariate Cox proportional hazard modeling adjusting for age and year of breast cancer diagnosis, estrogen receptor, progesterone receptor, ERBB2/HER2, Ki67, tumor grade, tumor size, and STO-3 trial treatment arm (tamoxifen or untreated).
Recursive partitioning was performed using the rpart package in R software (R Foundation) to construct a survival tree that best predicts 20-year breast cancer-specific survival. Input variables to the model includes 70-gene risk categories, BluePrint intrinsic subtype, age and year of breast cancer diagnosis, estrogen receptor, progesterone receptor, ERBB2/ HER2, and Ki67 status, tumor grade (1, 2, or 3), tumor size, and treatment arm. The final tree was selected by minimizing the 10-fold cross validation error.
Survival outcomes of patients in this cohort were followed through December 31, 2012. The 20-year, breast cancerspecific survival analysis is presented owing to concerns for model stability stemming from the small number of patients still alive and at risk within the ultralow-risk group after 20 years. Patients with contralateral primary breast cancers were censored at the time that the contralateral cancer was diagnosed to avoid confusion about ascribing breast cancer mortality to the contralateral cancer rather than the initial cancer event. Altogether, 61 patients with contralateral cancers (29 were tamoxifen treated [8.6%], 32 were untreated [10.2%]) were censored for the survival analysis.
All data preparation and analysis were done using SAS statistical software (version 9.4; SAS Institute Inc) and R, version 3.1.2.
Results
Patient and tumor characteristics of the postmenopausal women with available microarray data and within each treatment arm (n = 652) are in the eTable in the Supplement.No significant differences in age, type of surgery received, receptor status, tumor grade, and size were observed between the treatment arms. Most patients (516 [79%]) received mastectomy and axillary dissection. Of the tumors reassessed for estrogen receptor, progesterone receptor, ERBB2/HER2, and Ki67 status, 538 (83%) were estrogen receptor-positive; 369 (58%) were progesterone receptor-positive; 53 (8%) were ERBB2/ HER2-positive, and 178 (29%) had Ki67 greater than or equal to 15%; 121 (19%), 375 (58%), and 147 (23%) were grade 1, 2, and 3, respectively; and 499 patients (78%) had tumor size smaller than 2 cm and were not different from the original cohort (n = 1780). 
Long-term Survival Analyses of Cause-Specific Breast Cancer
The 70-gene signature scored 42% of patients as high-risk and 58% as low-risk. Kaplan-Meier breast cancer survival graphs of high-and low-risk patients censored at contralateral breast cancer diagnosis are shown in Figure 2A . There is a statistically significant difference in outcome between the groups (log rank P < .001). In particular, low-risk patients have an excel- lent (>95%) breast cancer-specific survival at 5 years. However, with extended follow-up, patients continue to die from their disease. Survival curves ( Figure 2B ) are shown for the 652 patients based on ultralow-, low but not ultralow, and high-risk assignments, 15% (98) of which were ultralow-risk. The difference in outcome based on the 3 designations is significant with a log rank P < .001. When stratified by treatment, in patients who received tamoxifen, there were no breast cancerspecific deaths at 15 years and breast cancer-specific survival was 97% at 20 years ( Figure 2C) ; patients without any systemic therapy had a 97% and 94% breast cancer-specific survival at 10 and 20 years, respectively ( Figure 2D ). Results without censoring for second cancers are shown in eFigure 2 in the Supplement.
Multivariate proportional hazards analyses of 20-year breast cancer-specific survival according to 70-gene risk groups adjusting for age and year of primary breast cancer diagnosis, estrogen receptor, progesterone receptor, ERBB2/ HER2, and Ki67 status, tumor grade, and tumor size, and treatment arm was performed. After adjustment, patients with high-risk and low-risk assignments had a statistically significant increased long-term risk of 4.73 (95% CI, 1.38-16.22) and 4.54 (95% CI, 1.40-14.80) of breast cancer-specific death, respectively, compared with patients with MammaPrint ultralow tumors. Figure 3A shows the intrinsic and biological characteristics of tumors that meet the MammaPrint ultralow-risk threshold. All ultralow tumors were hormone receptor-positive ERBB2/HER2-negative and of the luminal subtype by BluePrint. Using a 15% cutoff for Ki67 "low," 96% of ultralow-risk tumors with known Ki67 assessments were Ki67-low. When the PAM50 algorithm was used to assign intrinsic subtype, 89% of ultralow-risk tumors were designated as luminal A. Interestingly, only 19% of hormone receptor-positive ERBB2/HER2-negative tumors and 20% of Ki67-low tumors are ultralow risk ( Figure 3B) . Similarly, only 25% and 26% of tumors characterized as luminal A by PAM50, and Blueprint, respectively, meet the ultralow-risk threshold. On review of pathologic features of the ultralowrisk tumors, invasive ductal (no special type) carcinomas were the most frequent, but lobular, tubular, invasive papillary, and invasive cribriform subtypes were enriched, and mucinous types were absent. Log rank P = .001
Characteristics of MammaPrint Ultralow-Risk Tumors
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Kaplan-Meier plots of breast cancer-specific survival of the STO-3 trial cohort stratified based on the 70-gene score into (A) MammaPrint low-and high-risk groups and (B-D) ultralow, low but not ultralow, and high-risk categories for (B) all patients, and patients (C) with and (D) without tamoxifen treatment.
Tamoxifen was given to all patients in the tamoxifen treatment arm for 2 years; approximately 35% of patients received tamoxifen for an additional 3 years. COD BC indicates cause of death, breast cancer.
Recursive Partitioning
We used rpart, a recursive partitioning tool, with crossvalidation to integrate molecular and clinical variables and construct a survival tree that best predicts 20-year breast cancerspecific survival. The resulting model ( Figure 4A ) first divides patients by the ultralow-risk classification. No further subdivision of ultralow-risk patients is observed. In contrast, for tumors that do not meet the ultralow-risk classification, size is selected as the next most predictive factor, where patients with tumors greater than 2 cm have the worst outcome, with only about 70% breast cancer-specific survival at 10 years ( Figure 4B ).
Discussion
The ultralow-risk threshold of the 70-gene signature, in postmenopausal women with node-negative tumors 3 cm or smaller, reliably identifies women with minimal risk of death from breast cancer out to 20 years in the absence of any systemic therapy and negligible risk of death with 2 or more years of tamoxifen therapy alone. The ultralow-risk tumors are hormone-positive, mostly luminal A with low proliferation (Ki67 < 15%); however, they are only a small subset of cancers with those characteristics.
How is this relevant today? Women who have a tumor that is an ultralow-risk tumor by 70-gene signature can be reassured that their long-term outcome is expected to be excellent, with or without endocrine therapy. In the tamoxifentreated arm, most had only 2 years of therapy and still had excellent long-term survival. Many women are unable to tolerate 5 years of endocrine therapy, and fewer than 60% complete 5 years of treatment. 24 With the updated American Society of Clinical Oncology guidelines of 10 years of adjuvant endocrine therapy for patients with hormone receptorpositive breast cancers, 25 a test that accurately identifies a population of women who have very little risk to begin with should be welcomed by patients and clinicians alike. Importantly, this data set allowed us to evaluate the outcome of women with surgical therapy alone, and no systemic therapy, demonstrating an extremely low risk of recurrence. Furthermore, elderly women (>75 years) with comorbidities and a life expectancy of less than 10 years who present with an ultralowrisk breast tumor can be offered excision alone, with confidence that the treatment will be sufficient. In the STO-3 randomized clinical trial, all women received either mastectomy or lumpectomy and radiation, so there is no direct evidence to support reducing local therapy. However, the ultralow-risk tumors were a subset of luminal A tumors, and there is evidence that postmenopausal women with luminal A tumors have only a 5% chance of local recurrence with or without radiation. 26 Other randomized clinical trials also document similar groups of women who do not benefit from radiation, [26] [27] [28] and where the small fraction of women who recur can be successfully treated at the time of recurrence. However, despite level 1 evidence in 3 trials, the use of radiation for these subtypes has changed very little. The ultralow-risk classification, a smaller, more restricted subset of the Ki67 < 15% and luminal A cases, should surely qualify for "no radiation." The indolent behavior of these tumors and lack of systemic risk over 2 decades support a less aggressive approach to treatment. Almost all women in the STO-3 randomized clinical trial presented with palpable primary tumors, since breast cancer screening was not initiated in the Stockholm health care region until 1989. Importantly, 15% of these symptomatic (clinically detected) tumors were ultralow, showing that these tumors are an inherent part of the spectrum of breast cancers detected, regardless of screening. Women with ultralow-risk tumors who did not receive adjuvant therapy had excellent survival (94%), with the rare recurrence appearing 10 to 20 years after diagnosis. The group that had 2 or more years of tamoxifen had a 3% chance of death from breast cancer at 20 years. It is therefore unlikely that early detection of these types of lesions, before they come to clinical attention, would result in further clinical benefit. Even in the absence of screening, there are breast cancers that pose little or no systemic risk. The opportunity now is to recognize and properly classify these indolent tumors to avoid overtreatment.
The frequency of ultralow-risk cancers in a screened population of postmenopausal women is likely in the range of 25%.
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In the United States, over a 10-year period, 2 million cancers will be diagnosed, of which 500 000 might be indolent. Tools such as the ultralow-risk threshold of the 70-gene test can enable these tumors to be classified at diagnosis and provide reassurance that, once removed, the condition is rarely associated with distant recurrence or death ( Figure 4C ). This will provide support for patients and their physicians to choose less aggressive therapy. The overall objective of screening is to identify breast cancers at an earlier stage and thereby reduce the mortality that is associated with more clinically advanced disease. Mitigating the harms of screening 30,31 requires both the recognition that ultralow risk tumors exist, and the ability to reliably identify them with a diagnostic tool. Recursive partitioning ( Figure 4A ) demonstrates that the ultralow-risk classification is the most predictive factor at 20 years of follow-up. 8 Interestingly, once the ultralow-risk tumors are removed from the population, the next most predictive factor that drives prognosis is tumor size greater than 2 cm, suggesting that early detection is important for those tumors that are not ultralow risk (although some of this risk will be addressed with other systemic treatments not available at the time this study was conducted). The ability to identify an ultralow-risk category of tumors represents another critical advance in how molecular tools enable care to be personalized. 1, 4, [32] [33] [34] [35] [36] Since the outcome of tumors with indolent behavior is excellent, even when detected as a palpable mass, detection of their precursors would not deliver benefit. These data provide the impetus to explore whether we can identify the types of ductal carcinoma in situ that precede indolent lesions and refine our targets for screening. We are also investigating the genes that characterize ultralow-risk lesions and will explore commonalities across cancers that originate in other organ sites. 37 In prostate cancer screening, Gleason 3 + 3 is a marker of indolent disease. Men treated with active surveillance have now been shown to have excellent outcomes without excision, with 10-year disease-free survival rates of 97%. 38 Common biologic features of indolent behavior could inform a change in nomenclature. Interestingly, tamoxifen reduces the risk of contralateral cancers, but not until 15 years, possibly reflecting the long term preventive benefit of tamoxifen.
Limitations
Limitations of this study include the fact that we did not address whether breast cancer-specific survival was significantly affected by any additional endocrine therapy given at the time of first recurrence. Also, all women had either STO-3 trial stratified based on the 70-gene score into three categories (Ultralow risk, Low risk but not ultralow risk, and High risk). Tamoxifen treated patients have the same excellent survival. Women with second cancers appear to be at slightly higher risk after 10-15 years, perhaps reflecting the preventive impact of tamoxifen. 
